Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
References1 Phillips T, Jurczak W, Ribrag V, Linton K, Collin GP, Lopéz-Jimenéz J, Reddy N, Mengarelli A, Musuraca G, Sheehy O, Xu W, Azoulay M, Ghalie RG, Zinzani PL, Zelenetz AD. IBCL-271 Primary Efficacy and Safety Analysis of a Global Phase II Study of Zandelisib Administered by Intermittent Dosing (ID) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): The TIDAL Study. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S387-S388. doi: 10.1016/S2152-2650(22)01555-5. https://pubmed.ncbi.nlm.nih.gov/36164104
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.